Clinical Trial Update: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating CC-486 (oral azacitidine) added to standard therapy for patients aged 75 and older with newly diagnosed diffuse large B-cell lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CC-486 (oral azacitidine) (azacitidine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2, Phase 3 | Status: SUSPENDED